Reader View AI Reader View Oppenheimer reiterates Trevi Therapeutics stock rating ahead of trial update www.investing.com · September 25, 2026 · 10:54 Paywall detected This article has a paywall The publisher blocks direct access to this article. Generate with AI Open link